NeuroBo Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- NeuroBo Pharmaceuticals's estimated annual revenue is currently $2.6M per year.
- NeuroBo Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- NeuroBo Pharmaceuticals has 13 Employees.
- NeuroBo Pharmaceuticals grew their employee count by 30% last year.
NeuroBo Pharmaceuticals's People
Name | Title | Email/Phone |
---|
NeuroBo Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is NeuroBo Pharmaceuticals?
NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer's disease. Our Phase III-ready drug, NB-01, is based on natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP) and we have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration. 40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia. NB-02, our lead Alzheimer's drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer's disease (inhibition of AChE, pTau, amyloid-β, and stimulation of NGF for nerve growth. An aging population has resulted in an increase in the prevalence of Alzheimer's disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimer's disease, yet none of these four address disease modification.
keywords:N/AN/A
Total Funding
13
Number of Employees
$2.6M
Revenue (est)
30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NeuroBo Pharmaceuticals News
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO Get Rating) was the target of a significant growth in short interest during the month of March.
Brokerages Anticipate NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Will Announce Earnings of -$0.16 Per Share. Posted by admin on Apr 19th, 2022.
BOSTON, April 1, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.8M | 13 | -19% | $3M |
#2 | $2.1M | 13 | N/A | N/A |
#3 | $0.4M | 13 | -7% | $71.8M |
#4 | $1.3M | 13 | -46% | $96.5M |
#5 | $1M | 13 | -50% | $200M |